Literature DB >> 24651582

Decline in presumptively protective gut bacterial species and metabolites are paradoxically associated with disease improvement in pediatric Crohn's disease during enteral nutrition.

Konstantinos Gerasimidis1, Martin Bertz, Laura Hanske, Jana Junick, Olga Biskou, Margarita Aguilera, Vikki Garrick, Richard K Russell, Michael Blaut, Paraic McGrogan, Christine A Edwards.   

Abstract

BACKGROUND: The gut microbiota is implicated in the pathogenesis of Crohn's disease (CD). Exclusive enteral nutrition (EEN) is a successful treatment, but its mode of action remains unknown. This study assessed serial changes in the fecal microbiota milieu during EEN.
METHODS: Five fecal samples were collected from CD children: 4 during EEN (start, 15, 30, end EEN approximately 60 days) and the fifth on habitual diet. Two samples were collected from healthy control subjects. Fecal pH, bacterial metabolites, global microbial diversity abundance, composition stability, and quantitative changes of total and 7 major bacterial groups previously implicated in CD were measured.
RESULTS: Overall, 68 samples were from 15 CD children and 40 from 21 control subjects. Fecal pH and total sulfide increased and butyric acid decreased during EEN (all P < 0.05). Global bacterial diversity abundance decreased (P < 0.05); a higher degree of microbiota composition stability was seen in control subjects than in CD children during EEN (at P ≤ 0.008). Faecalibacterium prausnitzii spp concentration significantly decreased after 30 days on EEN (P < 0.05). In patients who responded to EEN, the magnitude of the observed changes was greater and the concentration of Bacteroides/Prevotella group decreased (P < 0.05). All these changes reverted to pretreatment levels on free diet, and EEN microbiota diversity increased when the children returned to their free diet.
CONCLUSIONS: EEN impacts on gut microbiota composition and changes fecal metabolic activity. It is difficult to infer a causative association between such changes and disease improvement, but the results do challenge the current perception of a protective role for F. prausnitzii in CD.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24651582     DOI: 10.1097/MIB.0000000000000023

Source DB:  PubMed          Journal:  Inflamm Bowel Dis        ISSN: 1078-0998            Impact factor:   7.290


  77 in total

Review 1.  Dietary management of IBD--insights and advice.

Authors:  Emma P Halmos; Peter R Gibson
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2015-02-03       Impact factor: 46.802

2.  Microbiome changes in healthy volunteers treated with GSK1322322, a novel antibiotic targeting bacterial peptide deformylase.

Authors:  Seda Arat; Aaron Spivak; Stephanie Van Horn; Elizabeth Thomas; Christopher Traini; Ganesh Sathe; George P Livi; Karen Ingraham; Lori Jones; Kelly Aubart; David J Holmes; Odin Naderer; James R Brown
Journal:  Antimicrob Agents Chemother       Date:  2014-12-08       Impact factor: 5.191

Review 3.  Exclusive enteral nutrition in children with Crohn's disease.

Authors:  Andrew S Day; Robert N Lopez
Journal:  World J Gastroenterol       Date:  2015-06-14       Impact factor: 5.742

4.  Toward enteral nutrition for the treatment of pediatric Crohn disease in Canada: a workshop to identify barriers and enablers.

Authors:  Johan Van Limbergen; Jennifer Haskett; Anne M Griffiths; Jeff Critch; Hien Huynh; Najma Ahmed; Jennifer C deBruyn; Robert Issenman; Wael El-Matary; Thomas D Walters; Cheryl Kluthe; Marie-Eve Roy; Elizabeth Sheppard; Wallace V Crandall; Stan Cohen; Frank M Ruemmele; Arie Levine; Anthony R Otley
Journal:  Can J Gastroenterol Hepatol       Date:  2015-06-15

Review 5.  Engineering the Microbiome: a Novel Approach to Immunotherapy for Allergic and Immune Diseases.

Authors:  Nan Shen; Jose C Clemente
Journal:  Curr Allergy Asthma Rep       Date:  2015-07       Impact factor: 4.806

6.  Reduction in Gut Microbial Diversity as a Mechanism of Action of Exclusive Enteral Nutrition.

Authors:  Nadeem O Kaakoush; Andrew S Day; Steven T Leach; Daniel A Lemberg; Hazel M Mitchell
Journal:  Am J Gastroenterol       Date:  2016-07       Impact factor: 10.864

Review 7.  The intestinal microbiome, barrier function, and immune system in inflammatory bowel disease: a tripartite pathophysiological circuit with implications for new therapeutic directions.

Authors:  Stephen M Vindigni; Timothy L Zisman; David L Suskind; Christopher J Damman
Journal:  Therap Adv Gastroenterol       Date:  2016-04-19       Impact factor: 4.409

8.  Inflammation, Antibiotics, and Diet as Environmental Stressors of the Gut Microbiome in Pediatric Crohn's Disease.

Authors:  James D Lewis; Eric Z Chen; Robert N Baldassano; Anthony R Otley; Anne M Griffiths; Dale Lee; Kyle Bittinger; Aubrey Bailey; Elliot S Friedman; Christian Hoffmann; Lindsey Albenberg; Rohini Sinha; Charlene Compher; Erin Gilroy; Lisa Nessel; Amy Grant; Christel Chehoud; Hongzhe Li; Gary D Wu; Frederic D Bushman
Journal:  Cell Host Microbe       Date:  2015-10-14       Impact factor: 21.023

Review 9.  Diet as a Therapeutic Option for Adult Inflammatory Bowel Disease.

Authors:  Samir Kakodkar; Ece A Mutlu
Journal:  Gastroenterol Clin North Am       Date:  2017-12       Impact factor: 3.806

Review 10.  Diagnostic and Prognostic Microbial Biomarkers in Inflammatory Bowel Diseases.

Authors:  Marla Dubinsky; Jonathan Braun
Journal:  Gastroenterology       Date:  2015-08-15       Impact factor: 22.682

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.